Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification.
Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with "peripheral T-cell lymphoma, unspecified" diagnosed by the WHO criteria were reviewed. Majority (69.4%) had stage IV disease with frequent involvements into bone marrow, spleen, liver, and skin. According to the IPI, 72.2% were categorized as high or high-intermediate risk group. CR and PR were achieved in 12 and 10 out of 31 patients treated by CHOP-based chemotherapy, respectively. One- and two-year overall survivals were 60.6 and 25.0%, respectively. Performance status, serum LDH, and B symptom were significant prognostic factors. Survival of CD4-/CD8+ cases, corresponding to cytotoxic T-cell lymphoma, was significantly worse than that of CD4+/CD8-.
Kojima
Hiroshi
H
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. hkojima@md.tsukuba.ac.jp
Hasegawa
Yuichi
Y
Suzukawa
Kazumi
K
Mukai
Harumi Y
HY
Kaneko
Shin
S
Kobayashi
Toshitaka
T
Kamoshita
Masaharu
M
Shinagawa
Atsushi
A
Komeno
Takuya
T
Komatsu
Tsunehiko
T
Mitsuhashi
Shoichi
S
Kawachi
Yasuhiro
Y
Yamashita
Yoriko
Y
Mori
Naoyoshi
N
Nagasawa
Toshiro
T
D000328:Adult; D000368:Aged; D016516:CD4-CD8 Ratio; D002965:Classification; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D016411:Lymphoma, T-Cell, Peripheral / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic; D016896:Treatment Outcome; D014944:World Health Organization